CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
AUSTIN, Texas, Sept. 06, 2017 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the BioCentury 24th Annual Newsmakers in the Biotech Industry conference, being held September 8th at the Millennium Broadway Hotel in New York City.
Presentation Details:
Date: Friday, September 8
Time: 2:00pm Eastern Time
Location: The Millennium Broadway Hotel, Presentation Room 311
Webcast: http://www.wsw.com/webcast/biocentury4/mtem/index.aspx
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
